Back to Results

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity

Study category: Nutrition and Metabolism

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Eligibility

Male and Female patients, 12 years of age and above Confirmed diagnosis of a rare genetic obesity caused by a mutation that impacts the function of the MC4 pathway

Phase

II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Marc-Andre Cornier,  MD

Marc-Andre Cornier, MD

Study ID

Protocol Number: 17-0373

ClinicalTrials.gov: NCT03013543

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers